[HTML][HTML] Metal-and metalloid-based compounds to target and reverse cancer multidrug resistance
Drug resistance remains the major cause of cancer treatment failure especially at the late
stage of the disease. However, based on their versatile chemistry, metal and metalloid …
stage of the disease. However, based on their versatile chemistry, metal and metalloid …
Reactive oxygen species production is responsible for antineoplastic activity of osmium, ruthenium, iridium and rhodium half-sandwich type complexes with bidentate …
Platinum complexes are used in chemotherapy, primarily as antineoplastic agents. In this
study, we assessed the cytotoxic and cytostatic properties of a set of osmium (II), ruthenium …
study, we assessed the cytotoxic and cytostatic properties of a set of osmium (II), ruthenium …
New insights into ruthenium (ii) metallodendrimers as anticancer drug nanocarriers: From synthesis to preclinic behaviour
Dendrimers have been studied as promising materials for the delivery of anticancer drugs. In
this work, low-generation (0–2) nitrile poly (alkylidenamine)-based dendrimers were …
this work, low-generation (0–2) nitrile poly (alkylidenamine)-based dendrimers were …
Ruthenium half-sandwich type complexes with bidentate monosaccharide ligands show antineoplastic activity in ovarian cancer cell models through reactive oxygen …
Ruthenium complexes are developed as substitutes for platinum complexes to be used in
the chemotherapy of hematological and gynecological malignancies, such as ovarian …
the chemotherapy of hematological and gynecological malignancies, such as ovarian …
Functional metal complexes from CuAAC “click” bidentate and tridentate pyridyl-1, 2, 3-triazole ligands
QVC van Hilst, NR Lagesse, D Preston… - Dalton …, 2018 - pubs.rsc.org
Ligands containing the bidentate 2-pyridyl-1, 2, 3-triazole and tridentate 2, 6-pyridyl-bis (1, 2,
3-triazole) moieties have emerged as alternatives to 2, 2′-bypridine and 2, 2′: 6′, 2 …
3-triazole) moieties have emerged as alternatives to 2, 2′-bypridine and 2, 2′: 6′, 2 …
Half sandwich-type osmium, ruthenium, iridium and rhodium complexes with bidentate glycosyl heterocyclic ligands induce cytostasis in platinum-resistant ovarian …
The toxicity of and resistance to platinum complexes as cisplatin, oxaliplatin or carboplatin
calls for the replacement of these therapeutic agents in clinical settings. We have previously …
calls for the replacement of these therapeutic agents in clinical settings. We have previously …
Unprecedented collateral sensitivity for cisplatin-resistant lung cancer cells presented by new ruthenium organometallic compounds
RG Teixeira, DC Belisario, X Fontrodona… - Inorganic Chemistry …, 2021 - pubs.rsc.org
Platinum-based therapies continue to be the main regimen used to treat non-small cell lung
cancers (NSCLC), where multidrug resistance plays a key role in treatment failure and …
cancers (NSCLC), where multidrug resistance plays a key role in treatment failure and …
Synthesis and antiparasitic activity of new trithiolato-bridged dinuclear ruthenium (II)-arene-carbohydrate conjugates
I Holzer, O Desiatkina, N Anghel, SK Johns… - Molecules, 2023 - mdpi.com
Eight novel carbohydrate-tethered trithiolato dinuclear ruthenium (II)-arene complexes were
synthesized using CuAAC 'click'(Cu (I)-catalyzed azide-alkyne cycloaddition) reactions, and …
synthesized using CuAAC 'click'(Cu (I)-catalyzed azide-alkyne cycloaddition) reactions, and …
Synthesis, biological activity and medicinal applications of ruthenium complexes containing carbohydrate ligands
AC Fernandes - Current Medicinal Chemistry, 2019 - ingentaconnect.com
The search for new metal-efficient drugs has attracted considerable attention of the scientific
community. Among them, ruthenium complexes have emerged as an excellent alternative of …
community. Among them, ruthenium complexes have emerged as an excellent alternative of …
Half-Sandwich Type Platinum-Group Metal Complexes of C-Glucosaminyl Azines: Synthesis and Antineoplastic and Antimicrobial Activities
While platinum-based compounds such as cisplatin form the backbone of chemotherapy, the
use of these compounds is limited by resistance and toxicity, driving the development of …
use of these compounds is limited by resistance and toxicity, driving the development of …